These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21118032)

  • 1. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.
    Sullivan SM; Doukas J; Hartikka J; Smith L; Rolland A
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1433-46. PubMed ID: 21118032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.
    Doukas J; Morrow J; Bellinger D; Hilgert T; Martin T; Jones D; Mahajan R; Rusalov D; Sullivan S; Rolland A
    Vaccine; 2011 Jul; 29(33):5443-52. PubMed ID: 21641955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.
    Sedegah M; Rogers WO; Belmonte A; Belmonte M; Banania G; Patterson N; Ferrari M; Kaslow DC; Carucci DJ; Richie TL; Doolan DL
    Vaccine; 2006 Mar; 24(11):1921-7. PubMed ID: 16298024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.
    Shlapobersky M; Marshak JO; Dong L; Huang ML; Wei Q; Chu A; Rolland A; Sullivan S; Koelle DM
    J Gen Virol; 2012 Jun; 93(Pt 6):1305-1315. PubMed ID: 22398318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.
    Porter KR; Ewing D; Chen L; Wu SJ; Hayes CG; Ferrari M; Teneza-Mora N; Raviprakash K
    Vaccine; 2012 Jan; 30(2):336-41. PubMed ID: 22085548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses.
    Sedegah M; Rogers WO; Belmonte M; Belmonte A; Banania G; Patterson NB; Rusalov D; Ferrari M; Richie TL; Doolan DL
    Vaccine; 2010 Apr; 28(17):3055-65. PubMed ID: 19879998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.
    Vilalta A; Shlapobersky M; Wei Q; Planchon R; Rolland A; Sullivan S
    Vaccine; 2009 Dec; 27(52):7409-17. PubMed ID: 19735757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
    Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
    Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial ghosts as adjuvant particles.
    Riedmann EM; Kyd JM; Cripps AW; Lubitz W
    Expert Rev Vaccines; 2007 Apr; 6(2):241-53. PubMed ID: 17408373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.
    Hartikka J; Bozoukova V; Ferrari M; Sukhu L; Enas J; Sawdey M; Wloch MK; Tonsky K; Norman J; Manthorpe M; Wheeler CJ
    Vaccine; 2001 Feb; 19(15-16):1911-23. PubMed ID: 11228361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical adjuvants for plasmid DNA vaccines.
    Greenland JR; Letvin NL
    Vaccine; 2007 May; 25(19):3731-41. PubMed ID: 17350735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porcine interleukin-3 enhances DNA vaccination against classical swine fever.
    Andrew M; Morris K; Coupar B; Sproat K; Oke P; Bruce M; Broadway M; Morrissy C; Strom D
    Vaccine; 2006 Apr; 24(16):3241-7. PubMed ID: 16457910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavivirus DNA Vaccine Design and Adjuvant Selection.
    Li L; Honda-Okubo Y; Petrovsky N
    Methods Mol Biol; 2021; 2183():405-422. PubMed ID: 32959256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
    Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
    Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaxfectin-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters.
    Shlapobersky M; Wei Q; Sullivan S; Vilalta A
    Vaccine; 2009 Oct; 27(46):6404-10. PubMed ID: 19607952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccines: a role for liposomes.
    Gregoriadis G
    Curr Opin Mol Ther; 1999 Feb; 1(1):39-42. PubMed ID: 11249682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments.
    Braun RP; Dong L; Jerome S; Herber R; Roberts LK; Payne LG
    Hum Vaccin; 2008; 4(1):36-43. PubMed ID: 18438102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fully mobilizing host defense: building better vaccines.
    Raychaudhuri S; Rock KL
    Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.